© Reuters.
ImmunoPrecise Antibodies (IPA) has reported a 20% increase in total revenue year-over-year for the third quarter of fiscal year 2024, despite a challenging macroeconomic climate. The company’s focus on its artificial intelligence subsidiary, BioStrand, and strategic investments in expanding its manufacturing presence in Europe have been pivotal in this growth.
While IPA achieved record-breaking revenues for the fourth consecutive quarter, the financial results also showed a net loss of $2.9 million. Nonetheless, the company has reduced its overall cash burn and established an equity offering facility to support further research and development.
Key Takeaways
- ImmunoPrecise Antibodies reported a 20% year-over-year revenue increase in Q3 of fiscal year 2024.
- The company experienced a net loss of $2.9 million but reduced overall cash burn.
- Strategic investments in BioStrand and expansion in Europe were key growth drivers.
- An at-the-market equity offering facility with Clear Street LLC was established.
- IPA is on track with its milestones and continues to focus on sustainable growth.
Company Outlook
- IPA is confident in its operational capacity for the next two to three years, following the expansion of its Utrecht and Vancouver facilities.
- The company is executing a strategy aimed at driving innovation and meeting industry needs.
Bearish Highlights
- Despite revenue growth, IPA reported a net loss of $2.9 million for the quarter.
Bullish Highlights
- Positive feedback and validation from pharmaceutical partners have led to larger programs and collaborations.
- The company’s foundational AI model, LENSai, shows potential for internal development and licensing.
Misses
- The Victoria facility still requires additional remodeling despite the expansions being in the phase of completion.
Q&A Highlights
- CEO Jennifer Bath indicated that the net proceeds from the equity offering were approximately $1.8 million at an average price of $2.09 per share.
- A Letter of Intent for a Material Transfer Agreement with a Talem asset is progressing, with a top five pharmaceutical company expressing interest.
ImmunoPrecise Antibodies (ticker: IPA) has demonstrated resilience and strategic acumen in its third-quarter performance. The company’s commitment to innovation, particularly through its AI subsidiary BioStrand, is not only driving revenue but also positioning IPA as a transformative force in drug discovery. With expansions underway and collaborations expanding, IPA is cementing its role in the industry while navigating the complexities of a challenging economic landscape. The company’s strategic direction, underscored by its financial results and operational updates, points toward a continued pursuit of growth and shareholder value. As IPA advances, the market will be watching its progress in the burgeoning field of AI-assisted drug discovery.
InvestingPro Insights
ImmunoPrecise Antibodies (IPA) has shown a noteworthy increase in revenue, yet the company’s stock performance and profitability outlook present a more complex picture. According to InvestingPro data, the market cap of IPA stands at 41.84M USD, which reflects the market’s current valuation of the company. The Price/Book ratio as of the last twelve months ending Q2 2024 is 1.09, suggesting that the stock is trading close to its book value, which can be appealing to value investors.
InvestingPro Tips indicate that the stock has experienced significant pressure, with a 13.59% decrease in price total return over the last week and a 19.7% decrease over the last month. This could be a point of concern for short-term investors, yet it may also present a buying opportunity for those who believe in the company’s long-term strategy and the potential of its AI subsidiary, BioStrand.
Furthermore, with a P/E ratio of -3.28 and an adjusted P/E ratio of -4.06 for the last twelve months as of Q2 2024, analysts are not expecting IPA to be profitable this year. This aligns with the net loss reported in the recent quarter. However, the company’s liquid assets exceed its short-term obligations, as highlighted by one of the InvestingPro Tips, providing some financial stability in the near term.
For investors interested in a deeper dive into the financial health and future prospects of ImmunoPrecise Antibodies, there are additional InvestingPro Tips available. By visiting https://www.investing.com/pro/IPA, readers can access these insights and consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With 8 more tips listed on InvestingPro, investors can gain a comprehensive understanding of the company’s financials and market position.
Full transcript – Immunoprecise Antibodies OTC (IPA) Q3 2024:
Operator: Good morning, ladies and gentlemen. Thank you for joining us today for IPA’s Earnings covering the Third Quarter of Fiscal Year 2024. I am Mandip, and I have the privilege of hosting this call. Before we commence, I would like to draw your attention to the fact that our discussions today may include forward-looking statements. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from what we expressed or implied. We strongly encourage you to review our filings with the Securities and Exchange Commission for a comprehensive discussion of these risks and uncertainties. IPA remains committed to complying with legal requirements and will update forward-looking statements only as mandated by law. During today’s conference call and the accompanying presentation slides, we will employ non-GAAP financial measures to assist investors and analysts in comprehending IPA’s business performance, adjusted EBITDA in particular allows the meaningful comparisons and analysis of trends in our business over different periods. For a detailed explanation and reconciliation of these non-GAAP measures to GAAP measures, please refer to the management discussion and analysis section of our filing on EDGAR and SEDAR. Now without further ado, I would like to pass the floor to IPA CEO, Dr. Jennifer Bath who will provide an overview of our quarterly results.
Jennifer Bath: Thank you, Mandeep, and good morning, everyone, and thank you for joining us for our third quarter earnings call for the fiscal year 2024. In this quarter, we’ve yet again proven our capability to flourish amidst a challenging macroeconomic environment, highlighting the relevance and effectiveness of our strategy, along with our adaptability. Our strategic foresight and comprehensive suite of end-to-end antibody services that we offer have been instrumental in securing this consistent growth. A significant portion of our R&D efforts this quarter has been directed towards supporting BioStrand, our artificial intelligence subsidiary, reflecting our belief in its transformative potential for drug discovery. By strategically focusing our investments and maintaining prudent cost management, we affirm our commitment to innovation, operational excellence, and the strategic development of our company to meet the evolving needs of industry and our clients. The past quarter was a landmark period where we not only continued our trajectory towards revenue growth, but also achieved notable improvements in our profit margins. This progress underscores our journey toward profitability with a clear focus on sustainable and profitable growth. Strategic investments in our BioStrand platform and an increase in our manufacturing footprint in Europe have been pivotal in securing a larger market share for catering to the increasing demand for our services. This strategic alignment ensures that we are well positioned to lead in the drug discovery and development space propelled by BioStrand’s innovative AI driven software capabilities. Reflecting on our financial and operational strategies, we’re proud to report a quarter of robust performance with a total revenue of $6.2 million, marking a 20% year-over-year increase. We are extremely proud to announce that this achievement marks our fourth quarter of back to back record breaking quarterly revenues at ImmunoPrecise Antibodies. This success is a testament to our strategic focus on sales, customer engagement, and operational efficiencies. Our BioStrand initiative has contributed to the success with early revenue from repeat business with large pharma companies, underscoring the compelling value proposition for our offerings. Our execution strategy underscored by strong customer relationships and effective marketing has not only facilitated growth, but also provided a feedback loop from our customers, enhancing our R&D focus on BioStrand and furthering our competitive edge. Our operational achievements are highlighted by the strategic implementation and integration of the BioStrand technology into our workflows, leading to significant scientific and commercialization advancements. The seamless integration and strategic expansion of our facilities, such as the Utrecht, and Victoria sites, along with notable growth in our Oss, the Netherlands facility, reflect our commitment to meeting client demands and driving revenue growth. The operational success is particularly notable in our B Cell program, contributing significantly to our discovery projects and revenue, showcasing the strategic and synergistic build of our company. Our scientific endeavors this quarter have been focused on expanding our VHH lead generation and offerings, and optimizing our in silico technologies, including the launch of LENSai epitope binning tool. These advancements not only reinforce our position at the forefront of VHH discovery, but also align our strategic vision of building safer, more efficacious drugs, faster, and with less risk. Our public speaking commitments at key technology industry conferences, such as HIMSS and Precision Medicine World conference in Silicon Valley demonstrates our commitment to innovation and our role as industry leaders, in part thanks to BioStrand’s entry into the market with validated in silico solutions. As we continue to invest strategically in BioStrand, aiming for a leading position in the industry with our upcoming software rollouts, we are mindful of our spending while ensuring these investments drive significant value and future revenues. BioStrand has developed a foundation AI model by integrating multiple large language models with its HYFTs technology. This model is designed to analyze complex biological data, particularly proteins, by identifying unique patterns and biological sequences, which improves the precision of a prediction and drug discovery and disease research. This approach allows for the creation of advanced products with reduced research and development costs compared to traditional AI solutions. BioStrand strategy involves balancing the growth of the CR revenue with the further development and integration of computational technology, contributing to advancements in the biopharmaceutical sector by accelerating the process of drug discovery and the development of personalized medicine solutions We are enhancing R&D efficiency through advanced data science. The foundation models prowess in transforming complex biological data sets into actionable insights with minimal computational expense is rooted in a suite of advanced data science methodologies. These methodologies are designed to optimize data processing and analysis, significantly reducing the reliance on extensive data generation and labor-intensive manual analysis. As we balance our steady CRO revenue growth with continued build-out and integration of in silico technologies, the advantage of the HYFTs allow us to be capital efficient while creating a hub of biotherapeutic intelligence. Now I’ll hand it over to our CFO, Kristin Taylor, who will delve into the financial specifics of this quarter in greater detail, highlighting our strategic investments in BioStrand, our operational efficiencies, and our unwavering commitment to delivering on our customers’ needs, a strategy that has not only driven our revenue growth, but has also strategically built our company for sustained success in the drug discovery and development industry.
Kristin Taylor: Thank you, Jennifer. I’ll provide a brief overview of our financial results for the third quarter of fiscal 2024 before touching on our financial position as of the end of the period, which was January 31st, 2024. As a reminder, all numbers I referenced are in Canadian Dollars unless otherwise noted. Starting with our revenue. For the three months ended January 31st, 2024, we achieved revenues of $6.2 million, representing a 20.3% increase in our revenue of $5.2 million in Q3 of previous year. year. Our year-to-date revenue was $18.1 million, reflecting a 20% increase from our fiscal 2023 year-to-date revenue of $15 million. Supporting this growth, our Utrecht, Netherlands site achieved year-to-date revenue growth of 32% year-over-year and is benefiting from expansion efforts in Q3 of last year, Our Victoria BC site achieved year-to-date revenue growth of 27% year-over-year and will be expanding its wet lab footprint in mid-calendar 2024. As for the impact of our ongoing expansion, our revenue history shows the results of our focus on continuing to identify and meet our customers’ needs. We have demonstrated sustained profitable revenue growth from our wet labs at higher than market rates and continue to expand, and to address not only our customers’ needs but also our stakeholders’ need. We are continuing to execute on our wet lab expansion by adding much needed lab space plus investing in the further development and launch of our LENSai portal and SaaS platforms. This strategy not just supports even higher revenue growth but gross margin improvements as well. Now on to our operating expenses. Our research and development expenses for the third quarter were approximately $1 million and $3.1 million year-to-date, which represents a $10 million decrease from the previous year. This decrease reflects the completion of the investments required to build the Talem Therapeutics assets, and now primarily represents our investment in supporting the phased rollout of our BioStrand offerings. Year-to-date sales and marketing expenses remain flat and represent our synergistic sales efforts across our comprehensive antibody discovery and development services, along with efforts towards Talem to out licensing opportunities. And general and administrative expenses for the quarter were $4.1 million and $11.5 million year-to-date. This reflects the decrease from the previous year-to-date balance of $11.7 million as we continue to see results from our strategic cost cutting efforts, even as they continue to grow our revenue and our A.I. offerings. On to earnings per share. Our growth in revenue and reduction in expenses resulted in a net loss of $2.9 million or $0.11 per share for the quarter versus our third quarter of fiscal 2023 that resulted in the loss $4.7 million, or $0.19 per year. Along with this reduction in net loss, we also experienced a reduction in our overall cash burns. This reduction in cash burn supported us in finishing the third quarter of our fiscal 2024 with unrestricted cash of $6.2 million versus our second quarter cash balance of $6 million and our fiscal 2023 yearend balance of $8.3 million. Additionally, subsequent to the end of our third quarter, on February 23rd, 2024, the company established an at the market equity offering facility, and ATM facility with Clear Street LLC, replacing its previous ATM facility with Jefferies LLC. This new relationship with Clear Street brings additional support in both raising equity and identifying value-added partnerships to build long-term shareholder value. To provide additional funding for our R&D efforts and wet lab expansion, we initiated a small equity raise in December of 2023, as well as utilized our new ATM facility in early March, 2024. We continue to monitor our cash from operations, as well as the cost of capital versus returns on R&D investment to assess the need to raise funds. With our consistent revenue growth and the R&D efficiency of the LENSai Universal Foundation AI model, we are able to slow down or speed up our R&D efforts as we work to best meet our customers and our partners’ needs while building shareholder value. With that, I’ll turn it back to Mandeep for Q&A.
Operator: [Operator Instructions] Our first question comes from the line of Will McHale with Ingalls & Snyder.
Will McHale: Good morning, Kristin and Jennifer. First quick one, Kristin, you mentioned that the company utilized the ATM offering in early March of 2024. Are you able to provide any more details on how much equity you raise?
Kristin Taylor: Yes, I am. As we reported in our SEC filing, we had net proceeds of approximately $1.8 million, and that is Canadian at an average price, net price of $2.09 a share.
Will McHale: Thank you. Last quarter, the company talked about executing an LOI to enter into a transfer agreement for a Talem asset. What’s the status of that program?
Jennifer Bath: Hi, Will, this is Jennifer, and thanks for asking about that. I’m sure that’s a question on other people’s mind as well. So the LOI, or Letter of Intent, pertains to entering into what’s called a Material Transfer Agreement, or MTA, for one of our valuable assets in the Talem pipeline. The company that signed the LOI does remain interested in moving forward with the MTA. However, they’ve indicated that they must first complete their delayed internal laboratory activities that are required for them to actually evaluate the tall amount of [inaudible] when they arrive. Given that the MTA actually specifies a fixed duration as soon as it’s activated, then their timeline for initiating the agreement is contingent on the completion of internal preparation so they’re actually ready to receive the material. To simplify that, if they sign the MTA, they have exactly six months to do the analysis. If three of those months are taken up with completing their internal materials to do the analysis, then they have only three months remaining to complete all of the work within the MTA without actually doubling their fees. So they’re trying to be strategic from that perspective. Of course, they no longer then have [inaudible] exclusivity on that target during that time. So related to that in parallel, we are pleased to share also that a top five pharmaceutical company has actually shown interest in the exact same asset. So they have also signed a confidentiality agreement or a CDA, and they’ve initiated discussions with Talem as well. So this development suggests there may be competitive interest in licensing the asset. So we’re closely monitoring the situation, answering their questions, and we’re committed to obviously pursuing the best outcome for our stakeholders. So we will provide updates as more information becomes available and as we make further progress.
Will McHale: Got it. Thank you. It’s been a year since announcing the Astellas collaboration. I realize that you’re probably limited in what details you’re able to share about the status of that, but I was wondering if you could comment on any sort of high level learnings from the program so far, specifically as it would relate to BioStrand and building their capabilities.
Jennifer Bath: Absolutely, actually, we’d be really happy to do that. So the developments in this collaboration specifically with Astellas are very broadly applicable to various aspects of what we do in the in silico antibody discovery and development. So for one example, for instance, the elements of the developed procedures are integrated into our recently launched LENSai epitope binning tool. In addition, for that collaboration with Astellas, we were able to leverage knowledge and insights that we obtained within our Talem programs. And then we refined our technology for detailed structural analyses of protein interactions. And then this development has brought along significant value to BioStrand. So it’s enabled them to make targeted adjustments to antibodies such as in silico adjustments of exactly where an antibody binds and exactly how strong that antibody is going to bind to its target. And these capabilities are ones that enable us to optimize in silico generated antibodies and then refine them further to make sure that they are optimized for the intended use in the clinic. So really a number of very tangible, very applicable aspects that we’ve learned through this program that are now built into the capabilities of BioStrand.
Will McHale: Great, that’s a good transition to my next question. Is the company still on track to hit the milestones listed in its investor deck? I know there was a number of things targeted for the first half of calendar ‘24, also for all of ‘24.
Jennifer Bath: Exactly. Starting first half of the calendar ‘24, also as you mentioned, kind of going through the first half of calendar ‘25. And so again, thank you for asking that question. So regarding our progress toward achieving the milestones included in the, it’s both structured AI and lab deals with a license fee, as well as securing custom LENSai software as a service deal, among others. And I am pleased to report that yes, we do believe we’re still on track to hit these milestones. We’ve been very laser focused on accomplishing these milestones. And the progress that we’ve made today has been really buoyed by the positive momentum we gained in this year’s partnering conferences, starting with Longwood and JP Morgan back in January. So not only did we have good valuable exposure, really at a time where we’re seeing the industry get much more excited about moving into partnerships, but these have also facilitated very meaning discussions with these potential partners, where we’re actively working with them to align company synergies and ways to explore the integration of our technologies and services in a way that’s mutually beneficial. So it’s definitely been supporting our active movement toward checking each of these investor milestones. And then the outcome from these conferences and these subsequent discussions have been quite promising. They’ve been reinforcing our confidence in that direction that we’re heading. And we do remain committed to maintaining this momentum. So we’re quite optimistic about our ability to deliver on the promises we’ve made to our investors and stakeholders. So rest assured, we are fully engaged in the efforts to not only meet, but also exceed the expectations that were set forward in that deck.
Will McHale: Great. Well, look forward to seeing the progress in the next couple of months. Last one from me, I was hoping you might be able to comment on sort of the commercial applications of the foundational AI model that you announced last week. Is that something that could be licensed to clients to use or is this mainly going to be an internal development tool?
Jennifer Bath: Yes, that’s a fantastic question. And so the quick answer to the last portion of that is really both. LENSai and then the foundational application of that is something that lends itself quite well to partnerships and collaborations. And we also see that as having very significant potential in really changing how everyone working with biological data is able to access and utilize that data in a more meaningful way. So much far beyond just the application of us using that as an internal tool for in silico antibody discovery and development, we really see it as being fundamental and foundational to everyone working with mass biologics in the space. So to give you just a little bit more detail on that, that’s kind of my direct go to answer. But just to provide a little bit more detail we’ve created and constructed this comprehensive technology stack, right, and that’s a lying really at the heart of this foundation AI. And the AI platform is designed for very broad applicability across the diverse services we offer at IPA. So a prime example of its effectiveness has been in that validation of the epitope binning, but also many other promising applications in the pipeline. And this quarter did represent quite a milestone really for BioStrand in utilizing these numerous in silico capabilities because we did receive enthusiastic validation not only from internal sources in terms of being able to validate the quality and the accuracy of the work coming out of the laboratory, but also from third party partners as well, which obviously was quite pleasing to them as well to see that they could really depend on in silico work, which obviously is quite a bit faster and cheaper and provides additional insights and then feel comfortable knowing that matches the wet lab data that’s coming back. So in this kind of AI era, kind of both in the investment realm and also in the client realm where you have this kind of mantra of, I’ll believe it when I see it, this has been really a massively rewarding quarter for not only IPA and BioStrand, but also for this pharma who are getting excited to see the validation of the in silico data coming out of BioStrand. And so the successes highlight not only the intrinsic value of us tapping into Talem data in our validation process, but it also really underscores the broad utility and adaptability of this foundation AI. And so just to wrap that up or kind of close that up maybe with something that I think is really tangible and applicable for people outside to really grasp that foundation AI role within LENSai, its introduction marks really a significant milestone with regard to our commercial strategy, because that Foundation AI extends LENSai’s capabilities into new realms. It provides a scalable and adaptable framework for data analysis and insight generation. So that LENSai is a foundational technology in the sense that it elevates the platform to the level of relevance and applicability, not only for life science and healthcare research, but anyone seeking to harness information from LLMs or generative AI or any other data-rich model. So it’s not just about enhancing our existing offerings, it’s about expanding the possibilities for what our technology can achieve in the marketplace. And with Foundation AI, LENSai is really poised to deliver unmatched value really to people harnessing data across a multitude of industries, opening up those opportunities for growth and innovation, and so it’s really this strategic integration that the signals are moved toward a more dynamic, data -driven solutions that can adapt to customer needs and also to market changes.
Will McHale: Great, yes, it sounds like a very promising breakthrough. I look forward to seeing the economic benefit for IPA shareholders as well. That’s all I have.
Operator: Our next question comes from a line of Swayampakula Ramakanth with H.C. Wainright.
Swayampakula Ramakanth: Thank you. This is RK from HC Wainwright. Good morning, Jennifer. Coupe of quick questions. As Kristen said, the Utrecht and the Vancouver facilities in terms of revenues grew north of 25% in both of those facilities. And we have seen that growth come in quarter after quarter since you did the expansion. So the question is on resources in the sense, as you see this expansion every quarter or the last two, three quarters now, are you getting to a point where you’re getting concerned about how much capacity you have in these facilities? Or do you still have enough capacity for growth, say for the next two to three years, if it grows at the same rate?
Jennifer Bath: Yes, I actually, I just, I love that question, RK, because it really does kind of tap into also the evolution of how we’ve gotten to this point with the needed expansion. Because for years, we talked about space utilization, equipment utilization, people utilization, automation, robotifying work, the ability to track different pieces of equipment from at home or at night so that we could have things running as much around the clock as possible and really optimize our efficiency without needing to do expansions and without needing to do significantly more hiring. So in the past quarters, one of the things that you’ll see that we’ve put up a couple of times was our revenue growth actually versus the number of FTEs that we had. And so we were really, really pushing the envelope at the Utrecht sites and the Victoria sites in particular where we were full to the brim with every piece of equipment being utilized, every square inch of each floor client being utilized. And then really at the point in Utrecht and in Victoria, British Columbia also where we had clients that had to sit in the queue and sometimes that was four months before we could actually bring those clients in. Now, I am happy to say that we have actually moved into that expansion realm with all three of our major production wet lab facilities. So Victoria did transition last January into a new facility, but that facility does actually require some additional remodeling and additional transition. It was something that we did not move into a brand new prepared facility. And so there is some duplication of some of the overhead associated with that with Victoria, but it’s duplication from the Victoria site and it’s also touch on the Oss site that you’ve already been seeing. And so with regard to any additional overhead associated with that, we’ve already been making those investments, they’ve already been incorporated into the lot of financial sales that you’re seeing. And we’ve managed that by being very strategic with regard to our pricing increases, having more of a focus on our profitability and our profit margins in order to offset that. So I think we’ve done that very strategically. So we’ve now started moving into that facility in Victoria where that expansion with regard to the footprint is significant and then also these additional room for expansion where we’ll actually be moving three full size laboratories into one laboratory to gain additional cost synergies and efficiencies. And then in Utrecht, we actually saw the same thing. They doubled the square footage of their manufacturing facility. That’s part of, as Kristin mentioned, what enabled us to really grow the revenues as rapidly as we did there this year, because they don’t any longer have these longer wait times for clients. And then the layout of the space is also just much more efficient with regard to the footprint and the production chain. And so with regard to that, we actually had been double paying and duplicating on the space to this one which was finished being built. It’s now been a year ago, October, since we’ve completed that. And again through optimizing our profit margins, and being more operationally efficient, we’ve really managed to do that without it really impacting our profit margins and our profitability, our profit in general, from those programs. And then the last one is Oss in the Netherlands, and they’ve actually done a full complete sweep move from their old facility into their new facility. And that was really spurred in part by the fact that the building that they were previously existing in was actually being rebuilt and the majority of the tenants were being moved over to the new building. But we do gain a lot of operational efficiency there and the space that we’re moving into there, no doubt, will be able to accommodate us for many years to come. So I think right now where we’re sitting, we went really very strategically as long as possible working with the minimum floor footprint, and a minimum number of personnel and just really kind of push ourselves to get to this point. And now I think these investments we’ve made are quite strategic, quite financially doable for us, but absolutely set us up for many years to come with regard to capacity. We won’t see any need to further expand those capacities anytime soon.
Swayampakula Ramakanth: Perfect. And then I know in the press release, you stated that you’re starting to see some service revenue out of BioStrand. If you can kind of expand on that, because since you all had BioStrand for almost a year and a half, two years, I know you’re doing a lot of tools building I’m sorry, I’m sure you’re doing much more than that, but I’m sorry to use the word tool building. But at the same time, I know you’re trying to generate some revenues, but for people like me to understand how much energy is being spent on gating that segment into revenue growth versus already getting some revenue out of that. I just want to understand where you are in that whole process.
Jennifer Bath: Yes, actually that is a great question. So with regard to BioStrand and where the emphasis is there on the development, as you mentioned we’ve been building these modules and these tools, really different components of LENSai in response to what our clients tell us that they need in response to what they believe would give them better insights earlier on so they can fail faster or succeed faster with better products that are more likely to be successful in the clinic. And so really, if we go back to two years ago, these were not capabilities that BioStrand had, we have the fundamental technology of LENSai powered by the HYFTs and this pattern recognition, with still the vectorization of the actual structural patterns to be completed and embedded. And as we continue to gain insights off of that and really turn our focus more specifically to biologic research associated specifically with therapeutic antibodies that was a significant part of that energy and effort put into that first 24 months, where we’ve been taking that and move that into the integration of these wet lab capabilities. But all-in-all, during this period of time where we’re performing those capabilities and building those modules, those are also are all parts of LENSai. And that LENSai remember being a tool that will be rolled out to our clients and then subsequently also to the public to enable people to not only utilize these tools within their own laboratory, but also to be able to encompass larger aspects of what we’re able to do with LENSai. So going back to the foundational technology and the ability to use LENSai to gather insights again for multiple LLMs and other resources, as well as to be able to use that for data management. And so we have these components that we’ve been building in and with regard to, as you mentioned, the revenue generation from these repeat clients. We have repeat clients that are certainly adding these capabilities into the workflow as they build novel drugs with our therapeutic wet lab arm, which is fantastic. We get that feedback. We have that learning loop. The HYFTs become more enriched and more informed as we continue to build the robust nature of LENSai. But in addition to that, we do have pharmaceutical clients that are using us in a very different type of capacity, both in the partnership model, as well as direct fee for service work directly at BioStrand and not quite as integrated into the wet lab capability. So I think when we first started talking about the power of LENSai, and again, going back to this idea of foundation AI, where it really is able to integrate these foundational layers that can improve insights and speed and applicability of other algorithms, other models in the industry, meaning that those insights within LENSai, they not only — they’re not just direct tap-in that people can do in LENSai, but they also complement other technology. So they’re not necessarily competitive with these other technologies. So it’s in supplying these types of tools for people to leverage both technological and biological aspects to enhance what they’re learning, which is also a major part of our partnership goals and collaboration goals with these different groups. And just as a really specific example, for instance we had mentioned previously really using LENSai to answer questions in the biological space that haven’t been able to be answered in the wet lab. And that’s why with the initial partners we took on, we took on partners who had really complicated programs that couldn’t, they could not actually solve in the wet lab capabilities or wet lab capacity. And so far, not only I’ve alluded to already after one of the questions from Will McHale that not only we really gained these wonderful insights that’s helped us to further build our tools, but we’re also having these wonderful successes in the lab, doing things where still so many people today refer to these as things that people will be able to do in the future with AI technologies things like really enhancing the developability of the asset, right, the potential safety and the lack of toxicity as it moves into the clinic. These are things that we’re refining and optimizing and using as we go through these partnerships. And in one of the partnerships in general right now, they now have brought forward their third and significantly largest program for us. And I think it’s worth emphasizing that in these types of partnerships are absolutely a focal point for us. It’s not just the integration of capabilities in the lab, these partnerships, foundationally, really help us demonstrate that we can tackle these obviously significant problems in the sciences and the biological industry and drug development using LENSai. And at the same time, we’re simultaneously building these additional tools. And so this group that’s come back for the third and like I said, significantly larger program, probably the most rewarding part of that for everyone at IPA is hearing their verbal feedback on BioStrand’s work, where they have just directly told us, hey, we have worked with, just anecdotally, we have worked with a lot of different AI companies out there to try and solve various tasks or answer various questions. And then working with BioStrand, this is the first group is what they tell us, where the data that comes back and the data that they validate in their lab is actually spot on with the work being turned down at BioStrand from an encyclical perspective. So that type of external validation, wet lab validation, and to have a group, a large pharmaceutical company really say, wow, this is the first time we’ve seen this, this is really it. This is really meaningful for us because now we know we can trust the data, that little AI skepticism that’s out there for so many people was really resolved. And that’s what led us to actually then getting this even larger, much more comprehensive program, which for us is incredibly rewarding. So it really is this balance of continuing to do the wet lab work, continuing to build that LENSai module, but these partnerships, these collaborations with these pharmaceutical companies, and we do believe that also over the next couple of quarters, we’re really looking to push also more into the technology industry for those collaborations as well. For us, we really believe these are incredibly meaningful. We not only gain additional insights, but we’re furthering to develop these relationships and get the validation we need to really show that this is real. It really does impact and change how we discover new drugs.
Operator: This concludes today’s question and answer session. I would now like to turn the call over to Jennifer Bath for closing remarks.
Jennifer Bath: Great. Thank you so much, Mandeep. So, first of all, as we wrap up today’s discussion on our third quarter earnings call for fiscal year 2024, I’d like to underscore the strategic execution and resilience that have defined our journey thus far. Our achievements this quarter are not just numbers, they’re a reflection of our unwavering dedication to innovation, strategic foresight, and operational excellence. With a significant 20% year-over-year revenue increase, our results speak volumes about our ability to navigate complex market dynamics and deliver on our promises. Our journey toward reduced net losses now at $0.11 per share is a clear indicator of our financial discipline and operational efficiency. This improvement is pivotal as it signals not only our capability to manage expenses wisely, but also our ongoing journey towards sustainable profitability. The strategic investments we’ve made so far, particularly in BioStrand and our expanded footprints, are laying down the foundation, not just for growth, but for transformative impact on the drug discovery and development landscape. Looking forward, our focus remains sharply on executing our strategy with precision, managing our resources effectively, and driving innovation that meets the evolving needs of our clients and the industry at large. Our commitment to you is to maintain this momentum to continue making strategic decisions that enhance value and to advance our mission of leading the way in drug discovery and development. We’re not just looking at the next quarter, we’re building a foundation for a future where ImmunoPrecise Antibodies stands as a beacon of innovation and excellence in our industry. We thank you for your continued trust and support. We’re excited about what lies ahead, and we look forward to sharing our progress with you.
Operator: This concludes today’s call. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
